Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry - 13/01/18
, Chitra Karki, MPH c, Marc Mason, MS c, Ning Guo, MS c, Stacey H. Holmgren, PharmD c, Jeffrey D. Greenberg, MD, MPH c, d, Mark Lebwohl, MD eAbstract |
Background |
Psoriasis is an immunodysregulatory inflammatory disease associated with comorbidities affecting quality of life. With the advent of new treatments, there is growing need to assess the long-term safety and efficacy of treatments in a real-world setting.
Objective |
The objective of the Corrona Psoriasis Registry is to study the comparative safety and efficacy of Food and Drug Administration–approved biologic treatments.
Methods |
A cross-sectional study of patients enrolled in the registry, who initiated or switched to a systemic therapy at enrollment or previous 12 months. Descriptive characteristics (demographics, clinical and patient-reported outcomes, comorbidities, and treatment history) were examined at registry enrollment.
Results |
As of October 1, 2016, there were 1942 patients enrolled in the registry: 23% on apremilast, 4% on other nonbiologic systemic medications, 25% on interleukin (IL) 17A inhibitors, 22% on an IL-12/23 inhibitor, and 26% on tumor necrosis factor inhibitors. Overall, mean disease duration was 15.6 years, and 40% had a concurrent psoriatic arthritis diagnosis. About 66% had >3% body surface area involvement and 49% had a moderate or severe Investigator Global Assessment.
Limitations |
Selection and channeling bias can result in potential confounding that needs to be addressed in modeled analyses.
Conclusion |
This disease-based registry cohort represents a population exposed to multiple therapies, long disease duration, and multiple comorbidities and can be used to examine comparative safety and efficacy of various therapies.
Le texte complet de cet article est disponible en PDF.Key words : biologic therapy, effectiveness, psoriasis, real-world, registry, safety, systemic therapy
Abbreviations used : BSA, BMI, DLQI, EQ-5D, EQ-5D-3L, IGA, IL, NPF, PASI, PRO, PsA, TNF, VAS
Plan
| Funding sources: Sponsored by Corrona LLC. Corrona Psoriasis Registry is sponsored by Corrona LLC and is funded by AbbVie, Boehringer Ingelheim, Celgene, Valeant, Merck, Eli Lilly and Company, and Novartis Pharmaceutical Corporation. During the last 2 years, Corrona LLC has been supported by AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Crescendo, Eli Lilly and Company, Genentech, GlaxoSmithKline, Horizon Pharma USA, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer, Roche, and UCB through contracted subscriptions. |
|
| Conflicts of interest: Dr Strober received honoraria for serving as consultant and on the advisory boards for AbbVie, Amgen, Astra Zeneca, Celgene, Dermira, Janssen, Leo, Eli Lilly, Cutanea-Maruho, Medac, Novartis, Pfizer, Sun Pharma, Boehringer Ingelheim, UCB, and Valeant; was an investigator for AbbVie, Amgen, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Lilly, Janssen, Merck, Sun Pharma, and Celgene (payments for which were received by the University of Connecticut and not Dr Strober); received consulting fees for serving as scientific director for Corrona Psoriasis Registry; and received grant support for the University of Connecticut for a fellowship program and not for Dr Strober from AbbVie and Janssen. Dr Greenberg is a shareholder of Corrona LLC and consultant for Genentech, Janssen, Novartis, Pfizer, and Eli Lilly. Dr Lebwohl is employee of the Mount Sinai Medical Center, which receives research funds from AbGenomics, Amgen, Anacor, Boehringer Ingelheim, Celgene, Ferndale, Lilly, Janssen Biotech, Kadmon, LEO Pharmaceuticals, Medimmune, Novartis, Pfizer, Sun Pharmaceuticals, and Valeant. Other authors have no conflicts of interest to report. |
|
| IRB Statement: All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor approval and continuing review was obtained through a central institutional review board (IRB; IntegReview, Corrona-PSO-500). For academic investigative sites that did not receive a waiver to use the central IRB, full board approval was obtained from the respective governing IRBs and documentation of approval was submitted to the sponsor before initiating any study procedures. All registry subjects were required to provide written, informed consent before participating. |
Vol 78 - N° 2
P. 323-332 - février 2018 Retour au numéro
Article précédent
- Psoriasis and the risk of diabetes: A prospective population-based cohort study
- Marilyn T. Wan, Daniel B. Shin, Rebecca A. Hubbard, Megan H. Noe, Nehal N. Mehta, Joel M. Gelfand
- Commentary: The Corrona-National Psoriasis Foundation Psoriasis Registry : A new collaborative approach for postapproval registries
- Bruce Strober
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?